NCT03900390 is a NA clinical trial of cross-preconditioning in Ischemic Preconditioning, sponsored by Mengya Liang.

Who is sponsoring NCT03900390?

NCT03900390 is sponsored by Mengya Liang.

What drugs are being tested in NCT03900390?

Interventions in NCT03900390: cross-preconditioning.

What condition does NCT03900390 study?

NCT03900390 studies Ischemic Preconditioning.

Is NCT03900390 still recruiting?

NCT03900390 is currently status unknown. Last updated 3 April 2019.

Last reviewed 2019-04-03 · How we verify

NCT03900390

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Study of Potency of Cross-preconditioning to Prevent Ischemic-reperfusion Injury for Heart Transplantation Recipient

Status unknown NA Last updated 3 April 2019

What this trial tests

NA trial testing cross-preconditioning in Ischemic Preconditioning in 80 participants. Status unknown.

Timeline

7 July 2017

Primary endpoint
7 July 2022

7 July 2023

Quick facts

Lead sponsor	Mengya Liang
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	80
Start date	7 July 2017
Primary completion	7 July 2022
Estimated completion	7 July 2023
Sites	1 location across China

Drugs / interventions tested

cross-preconditioning

Conditions studied

Ischemic Preconditioning — all drugs for Ischemic Preconditioning →

Sponsor

Mengya Liang

Who can join

Eligibility, any sex, with Ischemic Preconditioning. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In recent years, a large number of studies confirmed the protective effect of ischemic preconditioning on myocardium against ischemia/reperfusion injury, but the clinical data of the effectiveness of ischemic preconditioning in heart transplantation is still missing. Inspired by the promising data of ischemic preconditioning from the previous reports, the investigators firstly introduce a novel method of cross ischemic preconditioning technique to prevent ischemia/reperfusion injury to heart transplant recipients. This study will evaluate whether this cross-preconditioning technique would attenuate ischemia/ reperfusion injury to the heart transplant recipients, reduce Intensive Care Unit(ICU) and total hospitalization stays and the incidence of cardiovascular adverse events and improve the long-term survival outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Ischemic Preconditioning

Currently open trials in the same condition.

NCT05957523 — Effects of Remote Ischemic Preconditioning on Peripheral Blood Biomarkers in Healthy Adults (EMINENT) · NA · recruiting

Other Mengya Liang trials

Trials by the same sponsor.

NCT03235323 — Efficacy of External CounterPulsation for Postoperative Coronary Artery Bypass Grafting Patients · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03900390 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mengya Liang
Last refreshed: 3 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03900390.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing